Kristine R Crews

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    J Pediatr Hematol Oncol 26:764-7. 2004
  2. pmc Pharmacogenomics and individualized medicine: translating science into practice
    K R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 92:467-75. 2012
  3. pmc Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype
    K R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 91:321-6. 2012
  4. ncbi request reprint Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy
    Kristine R Crews
    Departments of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 8:2202-9. 2002
  5. pmc Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Cancer 116:227-32. 2010
  6. ncbi request reprint High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Judes Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 100:1724-33. 2004
  7. ncbi request reprint Individualizing chemotherapeutic treatment of colorectal cancer
    Kristine R Crews
    St Jude Children s Research Hospital, 332 N Lauderdale, Mail Stop 313, Memphis, TN 38105, USA
    Am J Health Syst Pharm 63:S12-7. 2006
  8. ncbi request reprint Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy
    Amar Gajjar
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 97:2374-80. 2003
  9. pmc Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Pediatr Blood Cancer 58:372-9. 2012
  10. pmc Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors
    Wayne L Furman
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105 3678, USA
    J Clin Oncol 27:4599-604. 2009

Detail Information

Publications29

  1. ncbi request reprint Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    J Pediatr Hematol Oncol 26:764-7. 2004
    ..The reduced area under the curve to the active metabolite SN-38 during ifosfamide therapy predicts a compromised efficacy of irinotecan in this combination...
  2. pmc Pharmacogenomics and individualized medicine: translating science into practice
    K R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 92:467-75. 2012
    ....
  3. pmc Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype
    K R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 91:321-6. 2012
    ..The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine...
  4. ncbi request reprint Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy
    Kristine R Crews
    Departments of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 8:2202-9. 2002
    ..The purpose of this study was to determine the effect of enzyme-inducing anticonvulsants (EIAs) on the disposition of irinotecan and metabolites in pediatric patients with high-grade glioma...
  5. pmc Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Cancer 116:227-32. 2010
    ....
  6. ncbi request reprint High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Judes Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 100:1724-33. 2004
    ..The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome...
  7. ncbi request reprint Individualizing chemotherapeutic treatment of colorectal cancer
    Kristine R Crews
    St Jude Children s Research Hospital, 332 N Lauderdale, Mail Stop 313, Memphis, TN 38105, USA
    Am J Health Syst Pharm 63:S12-7. 2006
    ..Patient-specific factors that enter into decisions about the chemotherapy used to treat colorectal cancer are illustrated in several case studies...
  8. ncbi request reprint Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy
    Amar Gajjar
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 97:2374-80. 2003
    ..The type and grade of toxicity did not differ between the two patient groups. Increasing the dosage of irinotecan increased the SN-38 AUC in some patients who received concomitant EIA therapy...
  9. pmc Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Pediatr Blood Cancer 58:372-9. 2012
    ..Administration of an oral cephalosporin allowed advancement of the dosage of oral irinotecan. This study investigates whether administration of an oral cephalosporin increases the maximum tolerated dose (MTD) of intravenous irinotecan...
  10. pmc Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors
    Wayne L Furman
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105 3678, USA
    J Clin Oncol 27:4599-604. 2009
    ..To assess the effect of gefitinib on the pharmacokinetics of IV irinotecan and on the bioavailability of a single oral dose of irinotecan...
  11. pmc Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients
    Anthony M Christensen
    Department of Pharmaceutical Services, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 118:4321-30. 2012
    ..The authors retrospectively reviewed glucarpidase use in pediatric cancer patients at their institution and evaluated whether subsequent resumption of HDMTX was tolerated...
  12. ncbi request reprint Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors
    Carlos Rodriguez-Galindo
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2795, USA
    Cancer Chemother Pharmacol 57:15-24. 2006
    ..Combining both agents may increase the amount of camptothecin delivered to the tumor, without additive toxicity...
  13. ncbi request reprint Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors
    Wayne L Furman
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794l, USA
    J Clin Oncol 24:563-70. 2006
    ....
  14. pmc Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer 116:98-105. 2010
    ..The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed...
  15. pmc RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients
    Xueyuan Cao
    Department of Biostatistics, St Jude Children s Research Hospital, Memphis, TN, USA
    Pharmacogenomics 14:1449-66. 2013
    ..Ribonucleotide reductase catalyzes an essential step in the cellular production of deoxyribonucleotide triphosphates and has been associated with clinical outcome in cancer patients receiving nucleoside analog-based chemotherapy...
  16. pmc Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments
    Jennifer L Pauley
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 3678, USA
    Cancer Chemother Pharmacol 72:369-78. 2013
    ..It is advantageous to individualize high-dose methotrexate (HDMTX) to maintain adequate exposure while minimizing toxicities. Previously, we accomplished this through within-course dose adjustments...
  17. ncbi request reprint Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma
    Jeffrey R Scott
    Pharmaceutical Department, St Jude Children s Research Hospital, Memphis, Tennessee
    Pediatr Blood Cancer 61:373-5. 2014
    ..Using this regimen, adequate peak methotrexate plasma concentrations were achieved and no further hypersensitivity reactions were noted...
  18. pmc Development and use of active clinical decision support for preemptive pharmacogenomics
    Gillian C Bell
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    J Am Med Inform Assoc 21:e93-9. 2014
    ..Active clinical decision support (CDS) delivered through an electronic health record (EHR) facilitates gene-based drug prescribing and other applications of genomics to patient care...
  19. pmc Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells
    Qing Cheng
    Hematological Malignancies Program, Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Am J Hum Genet 79:264-74. 2006
    ....
  20. ncbi request reprint Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 20:4217-24. 2002
    ....
  21. pmc PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity
    Gabriele Stocco
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Hum Mol Genet 21:4793-804. 2012
    ..These data indicate that polymorphism in PACSIN2 significantly modulates TPMT activity and influences the risk of GI toxicity associated with mercaptopurine therapy...
  22. pmc PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables
    Stan Pounds
    Department of Biostatistics, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Bioinformatics 25:2013-9. 2009
    ..However, to our knowledge, there is no statistical procedure designed to detect specific patterns of association with multiple endpoint variables...
  23. ncbi request reprint Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Pediatr Hematol Oncol 24:677-80. 2002
    ..More experience in the administration of 2-CdA to patients with renal insufficiency will be necessary to determine the need for dosage adjustment...
  24. ncbi request reprint High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma
    Thandranese S Owens
    Department of Pharmaceutical Sciences, Mail Stop 313, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105 2794, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 788:65-74. 2003
    ..5 to 5 ng/ml. Analysis of patients' plasma samples obtained before and after CPT-11 administration showed that the assay is suitable for measuring lactone and carboxylate forms of CPT-11, SN-38, SN-38G, and APC in clinical studies...
  25. pmc Development and implementation of a pharmacist-managed clinical pharmacogenetics service
    Kristine R Crews
    Pharmaceutical Department, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Am J Health Syst Pharm 68:143-50. 2011
    ..The development and implementation of a pharmacist-managed clinical pharmacogenetics service are described...
  26. ncbi request reprint Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status
    Gabriele Stocco
    St Jude Children s Research Hospital, Department of Pharmaceutical Sciences, 262 Danny Thomas Place MS 272, Memphis, TN 38105, USA
    Expert Opin Drug Saf 9:23-37. 2010
    ....
  27. ncbi request reprint Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors
    Lars M Wagner
    Division of Pediatric Hematology Oncology, University of Utah Primary Children s Medical Center, Salt Lake City, Utah, USA
    Clin Cancer Res 10:840-8. 2004
    ..The purpose is to estimate the maximum-tolerated dose (MTD) of temozolomide and irinotecan given on a protracted schedule in 28-day courses to pediatric patients with refractory solid tumors...
  28. ncbi request reprint Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group
    Alberto S Pappo
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 25:362-9. 2007
    ....
  29. ncbi request reprint Reducing irinotecan-associated diarrhea in children
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 50:201-7. 2008
    ..This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan...